Calcium phosphate cement (CPC) is an injectable, self-setting artificial bone material that has recently been used as a drug delivery system for bone infection therapy because of its high capacity for antibiotic elution. Despite this advantageous property, the mechanical strength of CPC dramatically decreases upon impregnation with certain types of antibiotics. A novel CPC material (CPC-A) with four-fold higher initial compression strength than that of conventional CPC (CPC-B) was developed by decreasing the median particle size of alpha-tricalcium phosphate powder in CPC from 6.34 to 2.30¯m. However, the elution profile and mechanical strength of the material following antibiotic impregnation remain unclear. In the present study, we compared the elution profiles and physical properties of CPC-A and CPC-B impregnated with vancomycin hydrochloride (VCM) and gentamicin sulfate (GM). CPC-A showed 3.6-fold higher initial (1 h after hardening) compression strength than CPC-B, even when impregnated with VCM. Scanning electron microscopy and porosimetry analyses revealed that the high compression strength of CPC-A was attributable to the densely arranged micro-porous structure. The small pores, which had a median size of 11.3 nm and served as passages for antibiotic elution, reduced the VCM elution rate and promoted long-term (18-week) antibiotic release compared to CPC-B, which contained larger pores (19.6 nm) and did not release VCM beyond 16 weeks. In contrast to VCM, GM impregnation did not markedly affect the compression strength of either material, and the GM elution profiles from CPC-A and CPC-B were nearly identical throughout the measurement period. Taken together, these findings demonstrate that the novel CPC material CPC-A has higher initial compression strength than conventional CPC and the potential for prolonged antibiotic release, suggesting that CPC-A would be an effective bone substitute material, particularly for bone infection therapy.
Introduction
Calcium phosphate cement (CPC) is a paste-like artificial bone material that is composed of alpha-tricalcium phosphate (¡-TCP), tetracalcium phosphate (TeCP), calcium hydrogen phosphate dihydrate (DCPD), and hydroxyapatite (HAp) powders in a dedicated solvent of sodium chondroitin sulfate and disodium succinate anhydride. 1)5) After injection of CPC paste, HAp and octacalcium phosphate (OCP) microcrystals precipitate and become entangled, resulting in a hardening of the material.
2), 6) Once set in defect sites, CPC shows excellent osteoconductivity, biocompatibility, and restorability. Due to these properties, CPC has been widely used in the field of not only orthopedic surgery, but also plastic surgery, oral surgery, and neurosurgery.
7)10)
Recent studies have examined the potential of CPC to function as drug delivery system for the treatment of bone infections.
11)13)
Although antibiotic-impregnated CPC has the capacity to release large amounts of antibiotics over long periods, the mechanical strength of CPC dramatically decreases upon impregnation with certain types of antibiotics. 14) Such a reduction in mechanical strength of the implant material would extend the recovery time and may increase the physical and mental strain of patients. In 2015, a novel CPC material (CPC-A) with 4-fold higher initial compression strength (50 MPa over 30 min) compared to conventional CPC (CPC-B) was commercially developed. 15) Alpha-TCP powder in CPC-A has a median particle size of 2.30¯m, which is several micrometers smaller than that of ¡-TCP powder in CPC-B, which has a median particle size of 6.34¯m. The finer densely arranged micro-porous structure of CPC-A results in higher mechanical strength. In contrast, no significant differences in the particle distribution and the compositions and forms of powder and solvent are detected between either CPC material. Although CPC-A was originally developed for vertebroplasty procedures, we speculated that the microporous structure of CPC-A would allow this CPC material to maintain its high mechanical strength even when impregnated with antibiotics.
In the present study, we first examined the elution profiles of vancomycin hydrochloride (VCM) and gentamicin sulfate (GM) from CPC-A and CPC-B, and then measured and compared the physical properties, including compression strength, setting time, and pore structure, of these materials to evaluate whether CPC-A is superior as a bone-substitute material with respect to antibiotic release ability and mechanical strength.
Experimental 2.1 Materials
The novel CPC material CPC-A (Biopex-R Excellent) and conventional CPC (CPC-B; Biopex-R Advance) were obtained from HOYA Technosurgical Corp. (Tokyo, Japan). Alpha-TCP powder in CPC-A and CPC-B has a median particle size of 2.30 and 6.34¯m, respectively. No significant differences in other components are observed between the two CPC materials. Injectable VCM and GM were purchased from Shionogi & Co., Ltd. (Osaka, Japan) and Nichi-Iko Pharmaceutical Co., Ltd. (Toyama, Japan), respectively. All other chemicals were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Compression strength
CPC-A and CPC-B test specimens impregnated with either VCM or GM were prepared as follows. CPC powder (12 g CPC-A or CPC-B), dedicated solvent (Biopex-R component; 4.0 mL), and VCM (0.5 g) were uniformly mixed into a paste, which was then applied to a cylindrical acrylic mold (¤7 mm © 14 mm). The samples were designated CPC-A+VCM and CPC-B+VCM. For the impregnation of the CPC materials with GM, CPC powder (12 g CPC-A or CPC-B), dedicated solvent (2.6 mL), and 40 mg/mL GM (0.6 mL) were uniformly mixed, and the resulting paste was applied to a cylindrical acrylic mold (¤7 mm © 14 mm). The samples were designated CPC-A+GM and CPC-B+GM. The prepared molds were heated in a chamber at 37°C and 95% relative humidity for 30 min to harden the antibiotic-impregnated test specimens (n = 10), which were then removed from the molds. CPC powder (12 g CPC-A or CPC-B) mixed with dedicated solvent (3.2 mL), but without antibiotics, was treated as above to prepare reference specimens (n = 10). The obtained specimens were immersed in simulated body fluid (SBF), 16) incubated at 37°C for 1 and 24 h, and then removed from the SBF for measurement of compression strength, which was performed using a universal testing machine (R33 4466, Instron, Kanagawa, Japan) with a crosshead speed of 0.5 mm/min.
CPC Setting time
For the analysis of setting time, the test specimens were mixed as described in Section 2.2. The prepared pastes were applied to cylindrical acrylic molds (¤10 mm © 3 mm) and were hardened by heating in a chamber at 37°C and 95% relative humidity. At regular intervals, a Vicat needle (¤2 mm, 300 g) was slowly lowered onto the surface of the paste, and the time at which the needle impression disappeared was designated as the setting time.
Pore structure and porosimetry analysis
For the analysis of pore structure, CPC pastes of CPC-A and CPC-B impregnated with VCM and GM were prepared as described in Section 2.2, with the exception that 0.3 g VCM and 1.6 mL of 40 mg/mL GM were used. The prepared pastes, which were designated CPC-A+VCM, CPC-B+VCM, CPC-A+GM, and CPC-B+GM, were hardened by heating in a chamber at 37°C and 95% relative humidity for 3 h. The molds were then removed to obtain the antibiotic-impregnated test specimens. Samples consisting of CPC powder (12 g CPC-A or CPC-B), dedicated solvent (4.0 or 3.2 mL) were also prepared as reference specimens without VCM and GM impregnation, respectively. The obtained specimens were dehydrated by immersion in 20 mL acetone for 10 min at room temperature, and were then air dried at room temperature. Thin sections (12 mm thickness) of each specimen were prepared using a microtome for scanning electron microscopy (SEM) analysis (S-4300, Hitachi High-Technologies, Tokyo, Japan) and the analysis of pore size using a mercury porosimeter (AutoPore IV9520, Micromeritics, Norcross, GA, USA).
Preparation of test specimens for elution analysis
The test specimens were prepared as described in Section 2.4. Each paste was prepared in triplicate and was then applied to a truncated cone-shape silicone mold. The paste was hardened by heating in a chamber at 37°C and 95% relative humidity for 3 h. The molds were then removed to obtain the test specimens.
Antibiotic elution
The impregnated CPC (1 g) test specimens were immersed in 10 mL sterile phosphate-buffered saline [PBS(¹)] and incubated at 37°C for 18 weeks. PBS(¹) was replaced daily. Eluates were collected on days 1, 3, 7, and 14, and weeks 4, 8, 12, 16, and 18. VCM and GM were detected by high-performance liquid chromatography (HPLC), as described in Sections 2.7 and 2.8, on the day of eluate collection.
Determination of VCM concentration
A series of standard solutions of known concentrations of VCM in PBS(¹) were prepared and injected into a CAPCELL-PAK C18 UG120 column (5¯m, ¤4.6 mm © 25 cm; Shiseido, Tokyo, Japan) of an Elite LaChrom HPLC system (Hitachi HighTechnologies) equipped with a L-2455 Diode Array Detector (Hitachi High-Technologies). The HPLC conditions were as follows: column temperature, 30°C; mobile phase A, triethylamine buffer (pH 3.2)/acetonitrile/tetrahydrofuran = 92/7/1 (v/v); isocratic elution, phase A (20 min); flow rate, 1 mL/min; wavelength, 280 nm; and injection volume, 20¯L. The peak area of VCM in each standard solution was measured and plotted against the VCM concentration to generate a calibration curve. The concentration of VCM in each test sample was determined by HPLC under the same conditions using the standard calibration curve.
Determination of GM concentration
HPLC systems were prepared as described in Section 2.7, with the exception that a L-2480 Fluorescence Detector (Hitachi HighTechnologies) was equipped. The three peak areas corresponding to the C1, C1a, and C2 components of GM were measured and plotted against the GM concentration to generate a calibration curve. The concentration of GM in each test sample was determined by HPLC using the standard calibration curve. As GM has no specific UV absorption, post-column derivatization with o-phthalaldehyde was used to generate fluorescent products for the determination of GM concentration, according to the method described by Anhalt.
17)
3. Results and discussion 3.1 Compression strength of CPC with and without antibiotic impregnation Figure 1(a) shows the compression strength of the CPC-A and CPC-B samples after a 1-h incubation at 37°C in SBF. The compression strength of CPC-A samples without antibiotics (54 « 1.7 MPa) was approximately 3-fold higher than that of CPC-B samples without antibiotics (18 « 1.6 MPa). Following impregnation with VCM, the compression strengths of both materials decreased by 50% or greater, although the CPC-A+VCM samples (25 « 1.6 MPa) retained 3.6-fold higher compression strength than that of the CPC-B+VCM samples (7 « 0.4 MPa). In contrast, for both CPC materials impregnated with GM, a lesser degree of compression strength reduction was observed (50 « 2.9 MPa for CPC-A+GM and 16 « 0.9 MPa for CPC-B+GM) as compared to each reference material without antibiotics. In addition, no significant differences in compression strength were detected between either CPC material after 24-h incubation in SBF [ Fig. 1(b) ].
Based on the above findings, the initial loss of compression strength induced by VCM impregnation was clearly minimized for CPC-A. Thus, we speculated that the entanglement of microcrystals, which is referred to as "crystal growth", within CPC-A proceeded at an increased rate, leading to a marked increase in the compression strength of the material compared to conventional CPC. As powdered VCM has particularly poor solubility in CPC, we previously found that non-reactive VCM particles physically block the crystal growth of CPC (manuscript submitted), resulting in reduced compression strength. However, the impregnation of CPC with a liquid antibiotic in soluble form, such as GM, would not inhibit the crystal growth of CPC. Consistent with this speculation, a loss of compression strength was not detected for either CPC-A or CPC-B following impregnation with GM.
Setting time with and without antibiotic impregnation
The setting times of the CPC pastes prepared with and without antibiotics were next determined and compared (Fig. 2) . The setting time of the materials impregnated with VCM tended to be delayed in comparison with those impregnated with GM; however, the increase in the setting time (34 min) was considered to be within the limits of practical use.
The interparticle distance of reactive CPC powders would be increased by the impregnation of insoluble VCM, thereby resulting in a prolongation of the hardening reaction. Here, no significant differences in the setting time were detected between CPC-A and CPC-B, regardless of the type of impregnated antibiotic. In contrast, a marked difference in the initial compression strength was observed between the two CPC materials, as shown in Fig. 1 . The hardening of CPC proceeds by a different reaction mechanism than that leading to the generation of mechanical strength. Specifically, CPC hardens via a rapid reaction that is triggered by DCPD, one of the powder composites of CPC, and proceeds by the following reactions:
The mechanical strength of CPC results from the precipitation and entanglement of the microcrystals of HAp and OCP that are produced during the hardening reaction.
2),6) As the composition and form of DCPD scarcely differed between CPC-A and CPC-B, the setting time of the two CPC materials was similar.
SEM and porosimetry analysis
After hardening, the crystal growth of CPC mainly proceeds by the hydration of ¡-TCP, as represented by the following typical formula:
Because CPC-A is comprised of finer particles of ¡-TCP powder, it was expected that this material would be more reactive than CPC-B, resulting in greater rigidity. Consistent with this speculation, SEM analysis of prepared CPC-A showed that the material contained densely arranged crystal particles, whereas that of CPC-B exhibited a crystal structure composed of largersized particles (Fig. 3) . As the impregnation of CPC with VCM blocked crystal growth, as described in Section 3.1, the introduction of VCM was predicted to increase the gaps between particles. As determined from the analysis of pore size distribution, it was determined that the median diameter of pores increased from 8.9 to 11.3 nm for CPC-A and from 15.3 to 19.6 nm for CPC-B ( Table 1) . The larger gaps between particles increase the fragility of the crystal structure. For this reason, CPC-A and CPC-A+VCM would be expected to have higher mechanical strength than that of CPC-B and CPC-B+VCM, respectively, a speculation that was consistent with the higher initial compression strength of CPC-A compared to that of CPC-B, irrespective of VCM impregnation (Fig. 1) . In contrast, impregnation with GM did not markedly affect the crystal structure or pore size of either CPC-A or CPC-B, and would therefore not influence the mechanical strength of the hardened materials (Fig. 4 and Table 2 ). This finding also confirmed the results shown in Fig. 1 . 
VCM elution from CPC
The elution of VCM from CPC-A and CPC-B was monitored by measuring the concentrations of antibiotic released in PBS(¹) over an 18-week period [ Fig. 5(a) ]. After reaching a peak at 24 h, the elution of VCM from CPC-A+VCM was reduced by approximately two-thirds compared with CPC-B+VCM. However, the difference in elution between the two materials gradually decreased, with the amount of VCM in the eluate of the CPC-A+VCM exceeding that of CPC-B+VCM after 4 weeks [ Fig. 5(b) ]. Notably, VCM in the eluate of the CPC-A+VCM samples was detectable until 18 weeks, whereas VCM was no longer detected in the eluate of the CPC-B+VCM samples after 16 weeks. Innumerable pores are present throughout hardened CPC and act as passages for antibiotic elution.
18) The micro-pores formed within the CPC-A+VCM samples, as shown in Table 1 , reduced the rate of VCM elution and prolonged the duration of antibiotic exposure. As the antibacterial activity of VCM is more influenced by the duration of exposure than the concentration, 19 ),20) the lower early elution of VCM from CPC-A would not likely affect the efficacy of antibacterial treatment, which would be expected to continue for several months after implantation.
GM elution from CPC
The time course of GM elution from CPC-A and CPC-B was also examined (Fig. 6) . Consistent with the profiles of VCM elution, the elution of GM from CPC-A+GM was reduced by approximately two-thirds compared to CPC-B+GM after reaching a peak at 24 h. However, the difference in concentration of GM in the eluate (³15¯g/mL) was much smaller than that observed for VCM (³100¯g/mL). After the first 24 h, the elution of GM from CPC-A and CPC-B gradually decreased at similar rates. Therefore, even though small differences in the pore size were observed between CPC-A+GM and CPC-B+GM, the elution profiles of GM from these two materials were nearly identical during the measurement period ( Table 2 ). The differing elution profiles of VCM and GM may be attributable to the sizes of the antibiotics. VCM has a MW of approximately 1450, whereas that of GM is only approximately 480. Thus, the difference in pore size between CPC-A and CPC-B would not be expected to markedly affect the elution of GM. As no significant differences were observed between the elution profiles of CPC-A and CPC-B, CPC-A has the potential to be an effective artificial bone substitute material with high compression strength.
Conclusions
The initial compression strength of CPC markedly decreases upon impregnation with certain types of antibiotics, including VCM. Here, we demonstrated that CPC-A in which the median particle size of ¡-TCP powder is 2.30¯m has 3.6-fold higher compression strength than the conventional CPC material CPC-B in which the median particle size of ¡-TCP powder is 6.34¯m, even when impregnated with VCM. The high compression strength of CPC-A was attributable to the densely arranged micro-porous structure, which was resulted from the reaction of fine CPC powder particles. The small pores of CPC-A, which are a median diameter of 11.3 nm and act as passages for antibiotic elution, reduced the VCM elution rate and increased the elution duration by approximately 2 weeks compared to the larger poresized CPC material CPC-B. In contrast, the impregnation of CPC-A with GM did not markedly affect the compression strength or elution profile of GM, which was nearly identical between CPC-A and CPC-B throughout the 18-week measurement period. Taken together, these findings demonstrate that the novel CPC material CPC-A has a higher initial compression strength than conventional CPC and the potential for prolonged antibiotic release, suggesting that CPC-A would be an effective bone substitute material, particularly for bone infection therapy. 
